Skip to search.
 Dow Down 0.60% Nasdaq Down 0.07%

Valeant Pharmaceuticals International, Inc. (VRX)

-NYSE

48.48 Up 0.44(0.92%) May 25, 4:08PM EDT|After Hours: 48.58 Up 0.10 (0.21%) May 25, 5:59PM EDT

ProfileGet Profile for:
Valeant Pharmaceuticals International, Inc.
4787 Levy Street
Montreal, QC H4R 2P9
Canada - Map
Phone: 514-744-6792
Fax: 514-744-6272
Website: http://www.valeant.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Delivery
Full Time Employees:6,900

Business Summary 

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders; Xenazine to treat chorea associated with Huntington’s disease; CeraVe to rebuild and repair skin barrier; and Kinerase, a cosmetic product. The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea and vomiting associated with cancer chemotherapy; Tiazac XC to treat hypertension and angina; Wellbutrin to treat depressive illness; Sublinox to treat insomnia; and Lodalis to treat hypercholesterolemia. Further, the company provides Cold-FX to strengthen immune system; Duromine/Metermine for weight loss; Difflam to treat sore throats; and Duro-Tuss and Rikodeine to treat dry and chesty cough, as well as various branded generics for treatments, including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications, and diabetic therapies. Additionally, it offers Bisocard to treat hypertension and angina pectoris; Flucinar, a corticosteroid ointment; and Sachol mouth ulcer gel; Bedoyecta to treat neurotic pain; M.V.I., a hospital dietary supplement for trauma and burns; Tandene to treat fever and headache; Melleril to treat anxiety and depression; and products for therapeutic classes, such as vitamin deficiency, antibacterials, and dermatology. It markets its products in the United States, Canada, Australia, New Zealand, Europe, Latin America, southeast Asia, and South Africa. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1960 and is headquartered in Montreal, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Valeant Pharmaceuticals International, Inc.

Corporate Governance 
Valeant Pharmaceuticals International, Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Medium Concern), Compensation (Low Concern), Shareholder Rights (Low Concern).
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. J. Michael Pearson , 52
Chairman and Chief Exec. Officer
18.53M0.00
Mr. Rajiv De Silva , 45
Pres, Chief Operating Officer and Chief Operating Officer of Specialty Pharmaceuticals
2.04M3.51M
Mr. Howard Bradley Schiller , 50
Chief Financial Officer, Principal Accounting Officer and Exec. VP
181.00K0.00
Mr. Brian M. Stolz , 36
Chief Human Capital Officer and Exec. VP of Admin.
540.00K0.00
Mr. Robert Roswell Chai-Onn , 41
Exec. VP of Corp. Bus. Devel., Gen. Counsel and Corp. Sec.
1.22M0.00
Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders